Documents

The Drug Enforcement Administration is adjusting the 2020 aggregate production quotas for certain controlled substances in schedule II of the Controlled Substances Act and the assessment of annual needs for the list I chemicals ephedrine and pseudoephedrine. This increase is in response to the current nationwide COVID-19 public health emergency as declared by the Secretary of Health and Human Services on January 31, 2020.

Statement of Thomas Prevoznik Deputy Assistant Administrator Diversion Control Division Drug Enforcement Administration U.S. Department of Justice Before the Subcommittee on Health House Committee on Energy and Commerce U.S. House of Representatives at a hearing entitled “Combatting an epidemic: legislation to help patients with substance use disorders” presented March 3, 2020

Matthew J. Strait, Senior Policy Advisor, Diversion Control Division-DEA; Before the House Energy and Commerce Committee-Subcommittee on Health, for a Hearing Entitled: Cannabis Policy-For the New Decade

Hearing Entitled “Tackling the Opioid Crisis: A Whole-of-Government Approach” December 17, 2019

Statement of Matthew Donahue before the House of Representatives, Energy and Commerce Committee, Subcommittee on Oversight and Investigations for a hearing entitled, Oversight of Federal Efforts to Combat the Spread of Illicit Fentanyl.

Greg Cherundolo Chief of Operations Office of Global Enforcement Drug Enforcement Administration U.S. Department of Justice before the United States Senate Judiciary Committee for hearing entitled:  The Countdown: Fentanyl Analogues and the Expiring Emergency Scheduling Order.

Greg Cherundolo Chief of Operations Office of Global Enforcement Drug Enforcement Administration U.S. Department of Justice before the United States Senate Homeland Security and Governmental Affairs Committee

Statement of Paul E. Knierim Deputy Chief of Operations, Office of Global Enforcement Drug Enforcement Administration Before the Subcommittee on Border Security and Immigration Committee on the Judiciary United States Senate

Statement before the Caucus on International Narcotics Control United States Senate for a hearing entitled “Stopping the Poison Pills: Combatting the Trafficking of Illegal Fentanyl from China”

Statement of Paul E. Knierim Deputy Chief of Operations, Office of Global Enforcement Before the Subcommittee on Africa, Global Health, Global Human Rights and International Organizations Committee on Foreign Affairs U.S. House of Representatives for a hearing entitled "Tackling Fentanyl: The China Connection"

Robert W. Patterson: Before the House Judiciary Committee U.S. House of Representatives for a Hearing Entitled “Challenges and Solutions in the Opioid Abuse Crisis”

Robert W. Patterson: Before the Subcommittee on Oversight and Investigations Committee on Energy and Commerce U.S. House of Representatives

Susan A. Gibson: Before the Subcommittee on Health Energy and Commerce Committee United States House of Representatives, for a Hearing Entitled “Combating the Opioid Crisis: Helping Communities Balance Enforcement and Patient Safety”

Daniel D. Baldwin: Before the Homeland Security and Governmental Affairs Permanent Subcommittee on Investigations United States Senate for a Hearing Entitled “Combating the Opioid Crisis: Exploiting Vulnerabilities in International Mail

Demetra Ashley: Before the Judiciary Committee, United States Senate, for a Hearing Entitled, “Oversight of the Ensuring Patient Access and Effective Drug Enforcement Act”

Neil D. Doherty: Before the House Energy and Commerce Committee, United States House of Representatives, for a Hearing Entitled “Federal Efforts to Combat the Opioid Crisis: A Status Update on CARA and Other Initiatives

Anthony D. Williams: Before the Senate Caucus on International Drug Control

Demetra Ashley, Acting Assistant Administrator of Diversion Control Subcommittee on Crime, Terrorism, Homeland Security, and Investigations, Committee on the Judiciary U.S. House Of Representatives “Stop The Importation and Trafficking of Synthetic Analogues Act of 2017”

Chuck Rosenberg: Before the Subcommittee on Crime, Terrorism, Homeland Security and Investigations Committee on the Judiciary U.S. House of Representatives, for a Hearing on Oversight of the Drug Enforcement Administration